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Abstract
Background: The effects of the vitamin A metabolite retinoic acid (RA) are mediated at the
transcriptional level by retinoic acid receptors (RAR). These proteins are part of a superfamily of
transcription factors which activate target gene expression when bound to their respective ligands.
In addition to ligand binding, heterodimerization with transcriptional cofactors and
posttranslational modification such as phosphorylation are also critical for transactivation function.
Previous studies have shown that phosphorylation of a serine residue at amino acid 77 in the RAR
amino terminus was required for basal activation function of the transcription factor.
Results: We have determined that RA inhibits cyclin H and cdk7 expression thereby decreasing
levels of phosphorylated RAR in human cancer cell lines. To determine the effects of decreased
RAR phosphorylation in human cancer cells, we stably transfected a phosphorylation defective
mutant RAR expression construct into SCC25 cultures. Cells expressing the mutant RAR
proliferated more slowly than control clones. This decreased proliferation was associated with
increased cyclin dependent kinase inhibitor expression and decreased S phase entry. In the absence
of ligand, the RAR mutant inhibited AP-1 activity to an extent similar to that of RA treated control
clones. Levels of some AP-1 proteins were inhibited due to decreased EGFR expression upstream
in the signaling pathway.
Conclusions: These results indicate that hypophosphorylated RAR can mimic the anti-AP-1
effects of RA in the absence of ligand.
Background
The effects of the vitamin A metabolite retinoic acid (RA)
are mediated by two classes of ligand dependent transcrip-
tion factors, the retinoic acid receptors (RAR) and the
retinoid X receptors (RXR) [1]. The RARs are activated by
all trans RA and 9-cis RA whereas the RXRs are activated
by 9-cis RA only. There are three known members of each
class (termed , , and ) encoded by separate genes. Each
gene may express several different isoforms because of al-
ternative splicing and differential promoter usage [2].
Both the RARs and RXRs contain functional domains for
DNA and ligand binding, dimerization with other tran-
scription factors, and transactivation of RA responsive
promoters. RARs and RXRs function as heterodimers that
bind to response elements in the promoters of target
genes to regulate RA dependent transcription. RAR/RXR
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and SMRT in the absence of ligand inhibits activation of
RA responsive genes [3,4]. Ligand binding displaces the
repressors and recruits coactivator proteins such as CBP
which have histone acetyltransferase activity [5]. Histone
acetylation allows for chromatin unwinding and tran-
scriptional initiation of target gene expression [6].
Previous studies have demonstrated that posttranslational
modifications of RARs and RXRs are critical to the biolog-
ical activity of the receptors. In the RAR amino terminus,
a consensus mitogen activated protein kinase (MAPK)
phosphorylation sequence was found to be a target of cy-
clin H and cdk7 [7]. RAR was shown to bind the cyclin
H/cdk7 complex in vitro and phosphorylation of serine
77 enhanced the transactivation function of RAR. This
phosphorylation was required for the RA mediated differ-
entiation of F9 cells into parietal endoderm [8]. These
studies point to the importance of phosphorylation in the
proper functioning of RARs.
Mutation of serine 77 to alanine in RAR has been shown
to inhibit the basal activation function of the receptor [7].
Other mutations have also been shown to decrease RAR
function. RAC65 cells, an RA resistant clone of the
pluripotent P19 embryonal carcinoma line, express a
truncated RAR that lacks part of the ligand binding do-
main [9]. As a result of this mutation, RAC65 cells do not
differentiate when exposed to RA. An RAR clone truncat-
ed after amino acid 403 was effective in repressing report-
er gene activity and blocking wild type RAR function
[10,11]. A single amino acid change in RAR (G303E) im-
paired RA binding affinity and significantly reduced re-
porter gene activity from responsive promoters. These
studies illustrate the usefulness of dominant negative RAR
mutants in elucidating mechanisms of RA signaling.
In the present study we show that RA, by inhibiting cyclin
H and cdk7 expression, reduces phosphorylation of RA-
R. We examined the role of hypophosphorylated RAR
by mutating the cdk7 phosphorylation site in the receptor
amino terminus (S77A). The S77A RAR mutant de-
creased proliferation of human cancer cells consistent
with inhibition of the G1/S phase transition. Decreased
proliferation of the mutant clones was associated with in-
hibition of EGFR mediated AP-1 expression and ERK1 ac-
tivity, similar to the effects of RA. This study illustrates a
novel mechanism by which RA inhibits proliferation (i.e.,
by decreasing RAR phosphorylation) and that in the ab-
sence of ligand, hypophosphorylated RAR can mimic
the molecular and cellular changes associated with retin-
oid treatment.
Results
The mechanisms which regulate cyclin H/cdk7 phosphor-
ylation of RAR have not been elucidated. To determine if
RA itself could affect the phosphorylation status of its re-
ceptor, we treated SCC4 and SCC25 lines with 1 M all
Figure 1
RA decreases cyclin H-cdk7 expression and inhibits RAR phosphorylation. (A) SCC4 and SCC25 cells were treated with vehi-
cle or 1 M RA (+RA) for 16 hours as described in Methods. Cyclin H and cdk7 expression was determined by western blot.
Blots were stripped and incubated with anti--actin antibody to ensure equal amounts of protein in each lane. (B) RA inhibits
RAR phosphorylation. RAR was immunoprecipitated (IP RAR) from lysates of vehicle and RA treated SCC4 and SCC25
cells as described in Methods. Blots were incubated with anti-phosphoserine antibodies (anti-pSer) followed by stripping and
probing with anti-RAR antibodies to ensure equal relative amounts of immunoprecipitated protein in each lane. To determine
the specificity of this assay, SCC25 cells were treated with vehicle or the selective MAPK inhibitors PD98059 (50 M) or
SB203580 (10 M) for up to 24 hours. RAR protein was immunoprecipitated as described above. These experiments were
performed three times with similar results. Representative blots are shown.Page 2 of 9
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decreased expression of both cyclin H and cdk7 in SCC4
and SCC25 cells by 3 fold. To determine if reduced cyclin
H and cdk7 expression correlated with decreased RAR
phosphorylation, we immunoprecipitated the receptor
from vehicle and RA treated SCC4 and SCC25 cells. As
shown in Fig. 1B, relative phosphorylation levels of RAR
decreased by 3 fold, similar to the reduction in cyclin H
and cdk7 expression. Previous studies have shown that
the amino terminus of the estrogen receptor is phosphor-
ylated by MAPK proteins [12]. To determine the participa-
tion of MAPKs in RAR phosphorylation, we performed
RAR immunoprecipitation on SCC25 cells treated with
the MEK/ERK inhibitor PD98059 or p38 inhibitory drug
SB203580. Treatment with these drugs did not change rel-
ative RAR phosphorylation levels (Fig. 1B). We conclud-
ed that RA repressed cyclin H/cdk7 expression which
correlated with reduced RAR phosphorylation levels.
RA is a potent inhibitor of cellular proliferation [13]. To
determine the effects of hypophosphorylated RAR on
the growth of human cancer cells, we expressed an S77A
RAR expression construct in SCC25 cells. The serine res-
idue at position 77 was previously shown to be the target
of cyclin H/cdk7 phosphorylation [7]. As shown in Fig. 2,
expression of the S77A mutant resulted in decreased rela-
tive phosphorylation of immunoprecipitated RAR in sta-
ble clones compared to G418 resistant control cells. To
confirm that this effect was due to expression of the hypo-
phosphorylated RAR mutant, we also created stable
clones expressing either HA tagged RAR or the S77A mu-
tant. As shown in Fig. 3, only clones expressing HA-RAR
and not the HA-S77A mutant showed phosphorylation
on serine residues. These experiments indicate that the rel-
ative amount of phosphorylated RAR in SCC25 cells was
decreased by the S77A mutant. SCC25 cells expressing the
S77A mutant RAR proliferated at markedly reduced rates
compared to control clones (Fig. 4). The S77A RAR mu-
tants grew at only 30–50% of the rate of G418 resistant
controls in culture. By comparison, proliferation of clones
expressing HA tagged RAR was 90% of G418 resistant
control cells. We concluded that decreased RAR phos-
phorylation produces inhibition of proliferation in
SCC25 cells.
To determine if decreased proliferation of the mutant
RAR clones correlated with inhibition of cell cycle pro-
gression, we performed BrdU incorporation analysis. As
shown in Fig. 5, less than half the percentage of S77A mu-
tant cells incorporated BrdU compared to the G418 resist-
ant control clones. By comparison, there were no
significant differences in BrdU incorporation between HA
tagged RAR clones and G418 resistant control cells.
These results indicate that the G1 to S phase transition of
the cell cycle is inhibited in S77A mutant clones. To cor-
roborate this conclusion, we examined expression of the
G1 phase cyclin dependent kinase inhibitors p21WAF1/
Cip1 and p27Kip1 in G418 resistant and S77A mutant
clones. We also determined the expression of the S phase
marker cyclin A in these cells. As shown in Fig. 6, expres-
sion of the G1 phase markers p21WAF1/Cip1 and p27Kip1 in
the mutant RAR clones was up to 3 fold higher com-
Figure 2
The phosphorylation defective RAR mutant inhibits prolif-
eration of human cancer cells. Expression of the S77A RAR
mutant decreased endogenous RAR phosphorylation in
SCC clones (RAR1-4) compared to G418 resistant control
cells (neo). RAR protein was immunoprecipitated as
described above.
Figure 3
The S77A mutant is not phosphorylated on serine in SCC25
cells. Cells were stably transfected with HA tagged RAR
(HA-RAR1,2), S77A mutant (HA-S77A1,2), or G418 resist-
ance (neo) expression vectors. HA tagged RAR proteins
were immunoprecipitated from cellular lysates using anti-HA
antibody (IP HA). Blots were incubated with anti-phospho-
serine antibodies (anti-pSer) to determine relative levels of
RAR phosphorylation on serine residues. Blots were
stripped and incubated with anti-RAR antibody to confirm
the identity of the anti-HA immunoprecipitates. Blots were
incubated with anti-HA antibody to ensure equal amounts of
immunoprecipitated protein in each lane. These experiments
were performed three times using different clones with simi-
lar results. Representative blots are shown.Page 3 of 9
(page number not for citation purposes)
Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/15pared to control cells. In contrast, expression of the S
phase marker cyclin A was decreased by 3 fold in two
clones (RAR1 and 2) and was undetectable in 2 others
(RAR3 and 4) when compared to G418 resistant control
cells. These results indicate that the decreased prolifera-
tion observed in S77A RAR mutant clones is due to inhi-
bition of cell cycle progression at the G1 to S phase
transition.
The antiproliferative effects of RA have been attributed to
its inhibition of AP-1 transcriptional activity [13]. While
the S77A RAR mutant has been shown to inhibit trans-
activation of RA response elements [7], its effects on AP-1
activity have not been characterized. We first addressed
this issue by transiently transfecting a heterologous pro-
moter containing a consensus AP-1 site fused to the luci-
ferase reporter gene [11] along with wild type RAR or
S77A mutant expression vectors. In the absence of ligand,
the S77A RAR mutant inhibited AP-1 activity from this
construct by 50%, similar to treatment with 1 M all trans
RA (Fig. 7). The wild type receptor possessed slight anti-
AP-1 activity in the absence of ligand (20% reduction
compared to control cells transfected with blank expres-
sion vector). These results indicate that hypophosphor-
ylated RAR can mimic the effects of RA by inhibiting AP-
1 activity.
To determine if reductions in AP-1 protein levels could ac-
count for the observed transcriptional inhibition by the
S77A mutant RAR, we compared expression of fos and
Figure 4
The S77A RAR mutant inhibits proliferation of SCC25 cells.
G418 resistant (neo), wild type HA-tagged RAR (HA1,2),
and S77A mutant clones (RAR1-4) were cultured as
described in Methods. At two day intervals, the cells in tripli-
cate cultures were counted with a hemacytometer. These
experiments were performed three times with similar
results. Error bars indicate SEM.
Figure 5
The phosphorylation defective RAR mutant inhibits G1 to S
phase progression in human cancer cells. Decreased BrdU
incorporation by carcinoma cells expressing the phosphor-
ylation defective RAR mutant. Cultures of G418 resistant
(neo), HA tagged RAR (HA1,2), and S77A RAR mutant
(RAR1-4) SCC25 clones were subjected to BrdU incorpora-
tion analysis as described in Methods. The number of BrdU
positive cells was expressed as a percentage of total cells
counted in ten high power fields. These experiments were
performed three times with similar results. Error bars indi-
cate SEM.
Figure 6
Cultures of G418 resistant (neo) and S77A RAR mutant
(RAR1-4) SCC25 clones were harvested for western blot as
described in Methods. Blots were incubated with primary
antibodies to the G1 cyclin dependent kinase inhibitors
p21WAF1/Cip1 and p27Kip1 and to the S phase cyclin A. These
experiments were performed three times using different
lysates with similar results. Representative blots are shown.Page 4 of 9
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RAR expressing cells. As shown in Fig. 8, Fra-1 expression
was undetectable in 3 of 4 RAR mutant clones. Expres-
sion of c-jun was reduced by 3 to 4 fold in the S77A RAR
cells compared to G418 resistant control clones. JunB ex-
pression was also decreased by up to 20 fold in mutant
RAR expressing cells. Expression of c-fos, Fra-2, FosB,
and JunD was not detected under normal growth condi-
tions in SCC25 cells. These results indicate that decreased
AP-1 protein expression correlates with AP-1 transcrip-
tional inhibition by hypophosphorylated RAR.
Upstream of AP-1 transcription factors, RA has been
shown to inhibit epidermal growth factor receptor (EGFR)
expression [14]. To determine if hypophosphorylated
RAR could inhibit EGFR expression, we examined ex-
pression of the growth factor receptor by western blot in
control and S77A mutant cells. As shown in Fig. 9, EGFR
expression was undetectable in 3 of 4 mutant RAR clones
and was reduced by 50% in the remaining clone (RAR1).
To determine if this dramatically decreased EGFR expres-
sion could inhibit downstream components of EGF sign-
aling, we also examined activation of ERK1 (a terminal
effector in the mitogen activated protein kinase pathway).
Activated ERK1 in S77A mutant cells was expressed at less
than 10% of the levels found in G418 resistant control
clones. Overall ERK1 expression was not affected by hypo-
phosphorylated RAR. These results indicate that compo-
nents of the EGFR signaling pathway, upstream of AP-1
transcription factors, are inhibited by hypophosphorylat-
ed RAR.
Activation of growth factor receptors has been shown to
induce expression of AP-1 proteins [15]. To determine if
EGF signaling correlated with AP-1 activity in SCC25 cells,
we first incubated cultures in 1% depleted serum for 16
hours to inhibit AP-1 protein expression. We then stimu-
lated these cultures with 10 ng/ml EGF for up to 4 hours.
As shown in Fig. 10, EGF produced dramatic induction of
AP-1 protein expression within 15 minutes after its addi-
tion. c-fos expression peaked at 100 fold over unstimulat-
ed levels at 2 hours following EGF addition. Following a
similar time course, c-jun expression increased by 25 fold
following stimulation by EGF. Induction of Fra-1 and
JunB expression was also noted, although the increase was
of less magnitude than that observed for c-fos and c-jun.
The effects of EGF on AP-1 protein expression were com-
pletely blocked by the EGFR kinase inhibitor tyrphostin
AG1478 (data not shown), indicating that growth factor
Figure 7
The phosphorylation defective RAR mutant inhibits AP-1
activity in the absence of RA. Triplicate cultures of SCC25
cells were transiently transfected with a heterologous pro-
moter construct containing an AP-1 response element in the
luciferase reporter vector pGL3 as described in Methods.
Wild type (alpha) or S77A mutant RAR expression vectors
were cotransfected with the reporter constructs. Blank
expression vector was used to control for the amount of
DNA transfected. Transfected cultures treated with vehicle
or 1 M RA for 24 hours were used as controls for AP-1
inhibition. Relative light units from vehicle treated cells trans-
fected with reporter construct and blank vector were
assigned an arbitrary AP-1 activity value of 100. These exper-
iments were performed three times with similar results.
Error bars indicate SEM.
Figure 8
The phosphorylation defective RAR mutant inhibits EGFR
expression, ERK1 activation, and AP-1 protein levels. (A)
Cultures of G418 resistant (neo) and S77A RAR mutant
(RAR1-4) SCC25 clones were harvested for western blot as
described in Methods. Blots were incubated with anti-human
primary antibodies to AP-1 proteins Fra-1, c-jun, or JunB.
These experiments were performed three times using differ-
ent lysates with similar results. Representative blots are
shown.Page 5 of 9
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pression. These data suggest that in the unliganded state,
hypophosphorylated RAR can mimic the effects of RA on
EGFR expression, ERK1 activity, and AP-1 protein levels.
Conclusions
The antiproliferative effects of RA have been recognized
for many years. This important chemotherapeutic proper-
ty of RA has been attributed to a number of molecular
mechanisms. Decreased growth factor and growth factor
receptor expression has been proposed as a potential
growth inhibitory mechanism [14]. Additionally, RA me-
diated inhibition of AP-1 activity is believed to be impor-
tant in cellular growth control by this ligand [13]. AP-1
inhibition via direct interaction between RARs and AP-1
proteins has been proposed [16]. RA inhibition of jun N-
terminal kinase was shown to prevent c-jun phosphoryla-
tion, resulting in decreased AP-1 activity [17]. Competi-
tion between RAR and AP-1 for limiting amounts of the
nuclear receptor coactivator CBP may also account for de-
creases in AP-1 transcriptional activity [5]. In the present
study we have described a new mechanism by which RA
can inhibit cellular proliferation. RA inhibited cyclin H
and cdk7 expression which correlated with hypophospho-
rylation of RAR on serine 77. To separate the specific role
of hypophosphorylated RAR from the pleiotropic effects
of the ligand, we expressed a non-phosphorylatable S77A
mutant protein in human cancer cells. The S77A RAR
mutant inhibited proliferation of SCC25 cells even in the
absence of RA, thereby mimicking the growth inhibitory
effect of the ligand. This growth inhibition correlated with
a delay in G1 to S phase progression. EGFR expression,
ERK1 activation, and AP-1 activity were inhibited by the
mutant RAR, effects which are also achieved by RA treat-
ment alone. We determined that decreases in AP-1 protein
expression observed in the RAR mutant clones were pri-
marily due to diminished EGFR signaling. Therefore while
ligand bound RAR has been shown to activate a large
number of RA target genes, the hypophosphorylated form
of the receptor created in some cells following retinoid
treatment may be important in transcriptional repression.
In support of this hypothesis, Rochette-Egly et al. [7] de-
scribed decreased transactivation function by the S77A
mutant RAR.
Previously we characterized another RAR mutant in
which the receptor protein was truncated after amino acid
403, thereby deleting the AF-2 domain [11]. This truncat-
ed receptor exhibited similar properties to the S77A mu-
tant (growth inhibition and repression of RA responsive
gene expression including EGFR). Repression of RA re-
sponsive gene expression was believed due to the inability
of this RAR to interact with CBP via its shortened carboxyl
terminus [5]. By the same token this mutant receptor did
not affect RA inhibition of AP-1 activity, presumably due
to its inability to compete for CBP [11]. We observed de-
creased AP-1 activity in transient transfections using the
RAR403 mutant likely due to decreased EGFR expression.
However, the mechanisms by which the S77A mutant in-
hibits RA responsive gene expression is unknown. The
RAR amino terminus is not known to interact with CBP
or its associated factor PCAF [5,18]. Additionally, RARs
bind to the interaction domains of repressor proteins such
as NCoR via region D of the receptor rather than the ami-
no terminus [4]. Despite the lack of obvious interaction of
the RAR amino terminus with nuclear receptor cofactors,
the S77A mutation may alter the three dimensional struc-
ture of the receptor. This altered configuration may pre-
vent the mutant receptor from releasing repressor proteins
or recruiting coactivators in the presence of ligand. The
S77A mutant receptor was shown to inhibit ligand de-
pendent transactivation of RA responsive promoters [7],
but the mechanism of this reduction (e.g., competition for
binding sites, cofactor interaction, ligand binding) has
not been determined.
In summary, decreased RAR phosphorylation correlat-
ing with RA mediated inhibition of cyclin H and cdk7 ex-
pression illustrates a new mechanism by which ligand can
indirectly regulate receptor activation. This raises the
question of how RA initially downregulates cyclin H and
cdk7 expression, whether by AP-1 inhibition or through
negative retinoid response elements in the regulatory re-
gions of the genes. The characterization of potentially al-
tered interactions between hypophosphorylated RAR
Figure 9
EGFR expression and ERK1 activation are inhibited in S77A
RAR mutant cells. Cells were harvested for western blot as
described above. Blots were incubated with anti-human pri-
mary antibodies to EGFR, activated ERK1 (anti-pERK1), and
total ERK1. These experiments were performed three times
using different lysates with similar results. Representative
blots are shown.Page 6 of 9
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post-translational modification of nuclear hormone re-
ceptors regulates repressor release, coactivator recruit-
ment, histone acetylation, and transcriptional activation.
Methods
Cell culture and stable transfection
The human squamous cell carcinoma lines used in this
study were purchased from the American Type Culture
Collection and have been described previously [11]. Cells
were cultured in Dulbecco's modified Eagle medium
(DMEM), 10% fetal bovine serum (FBS), and 40 g/ml
gentamicin at 37C in a humidified atmosphere of 5%
CO2. S77A mutant or wild type RAR cDNAs were cloned
into the pCruz-HA expression vector. These vectors or
blank plasmid were transfected into SCC25 cells using
Lipofectamine reagent according to manufacturer's rec-
ommendations (Invitrogen). Cells were selected in 400
g/ml G418 for 14 days. Resistant clones were picked for
expansion and characterization.
Western blot
SCC4 and SCC25 cells were treated with 1 M all trans RA
for 16 hours. In a separate set of experiments, SCC25 cells
were cultured for 16 hours in DMEM, 1% charcoal-resin
treated FBS followed by stimulation with 10 ng/ml epider-
mal growth factor (EGF) for up to 4 hours. 75 g total cel-
lular protein was separated by SDS-PAGE on 10%
resolving gels under denaturing and reducing conditions.
Protein lysates from G418 resistant and S77A mutant
RAR clones were also analyzed. Separated proteins were
electroblotted to PVDF membranes according to manu-
facturer's recommendations (Roche Molecular Biochemi-
cals). Blots were incubated with antibodies to human
cyclin H, cdk7, cyclin A, p21WAF1/Cip1, p27Kip1, EGFR, ac-
tivated and total ERK1, c-fos, Fra-1, c-jun, JunB, or -actin
(Santa Cruz Biotechnology) for 16 hours at 4C. After
washing in Tris buffered saline containing 0.1% Tween 20
(TBST, pH 7.4), blots were incubated for 30 minutes at
room temperature with anti-IgG secondary antibody con-
jugated to horseradish peroxidase. Following extensive
washing in TBST, bands were visualized by the enhanced
chemiluminescence method (Roche Molecular Biochemi-
cals) and quantitated by laser densitometry.
Immunoprecipitation
SCC4 and SCC25 cells were treated with 1 M all trans RA
for 16 hours. To determine if ERK1 or p38 MAPKs phos-
phorylated RAR, some cultures were treated with 50 M
PD98059 or 10 M SB203580 for the same time period.
Cultures of G418 resistant and S77A RAR mutant clones
were used in separate immunoprecipitation experiments.
Cultures were lysed in 50 mM HEPES (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 1% Noni-
det P-40, 10% glycerol, 1 mM NaF, 0.1 mM sodium or-
thovanadate, and protease inhibitors for 30 minutes at
4C. Lysates were centrifuged at 10,000  g for 10 minutes
and anti-RAR or anti-HA antibodies (Santa Cruz Bio-
technology) were incubated with the supernatants for 1
hour at 4C. Antigen-antibody complexes are precipitated
with protein A/G agarose beads for 1 hour at 4C. Immu-
noprecipitated proteins were washed three times with 1
ml lysis buffer. Samples were boiled in 1 Laemmli buffer
for 3 minutes, separated by SDS-PAGE, and blotted to pol-
yvinylidene difluoride membranes. Blots were probed
with anti-phosphoserine antibody (Zymed) to determine
relative phosphorylation levels of immunoprecipitated
RAR. Blots were then stripped and incubated with anti-
RAR antibodies to ensure equal amounts of immunopre-
cipitated protein in each lane. Bands were visualized by
the enhanced chemiluminescence method and quantitat-
ed by laser densitometry.
Proliferation and bromodeoxyuridine incorporation analy-
ses
5  104 G418 resistant SCC25 control cells, RAR overex-
pressing cells, or S77A mutant RAR clones were plated in
triplicate into 6 well tissue culture plates and grown for 6
days. At two day intervals, cells were trypsinized and
counted with a hemacytomter. SCC25 control, RAR
Figure 10
EGFR activation induces AP-1 protein expression in human
cancer cells. SCC25 cells were cultured in low serum
medium prior to stimulation with 10 ng/ml EGF for up to 4
hours as described in Methods. Whole cell lysates were sub-
jected to western blot analysis using anti-human primary anti-
bodies to c-fos, Fra-1, c-jun, and JunB. These experiments
were performed three times using different lysates with simi-
lar results. Representative blots are shown.Page 7 of 9
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tured on plastic then incubated with 10 M BrdU for 1
hour. After washing in PBS, cells were fixed in 70% etha-
nol, 50 mM glycine (pH 2) for 30 minutes at -20C. Fol-
lowing extensive washing in PBS, cells were incubated
with mouse anti-BrdU primary antibody at 37C for 30
minutes. After washing in PBS, cells were incubated with
anti-mouse IgG secondary antibody conjugated to fluo-
rescein at 37C for 30 minutes. Following extensive wash-
ing in PBS, BrdU positive cells were visualized by
fluorescence microscopy. The number of positive cells was
expressed as a percentage of total cells counted in ten ran-
domly selected high power fields.
Reporter gene analysis
Triplicate dishes of SCC25 cells were transiently transfect-
ed with 5 g luciferase reporter construct containing a het-
erologous promoter containing a consensus AP-1 site 5'-
TGACTCA-3' [11]. 2 g of wild type or S77A mutant RAR
expression vector was cotransfected to determine the ef-
fects of RAR phosphorylation on AP-1 promoter activity.
1 g of a -galactosidase expression vector was also in-
cluded to normalize for transfection efficiency. Some cul-
tures were treated with 1 M all trans RA or 0.1% ethanol
vehicle for 24 hours. Reporter assays were performed us-
ing the Dual-light kit according to manufacturer's recom-
mendations (Tropix). Luciferase activity was normalized
to that of -galactosidase for each sample.
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